PTC/SB/08a (08-03 )
Approved for use through 97/31/2006, ONE 0651-0201
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unfers it contains a valid OMS control number. Under the Paperwork Reduction Act of 1995, no persons are requ

			Application N	umber				
			Filing Date					
		TION DISCLOSU	First Named	Inventor	Jeffre	y Wilson		
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)			Art Unit					
			Examiner Na	me				
			Attorney Doc	Attorney Docket Number DYOUP0317US				
				U.S.I	PATENTS			Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document		tee or Applicant	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
					l			

						I iguies Appeal		
	1							
If you wis	h to a	dd additional U.S. Paten	t citatio	n information pl	lease click the Add button.	Add		
	U.S.PATENT APPLICATION PUBLICATIONS Remove							
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wis	h to a	dd additional U.S. Publis	hed Ap	plication citation	n information please click the Ad-	d button. Add		

	FOREIGN PATENT DOCUMENTS Remove										
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code4	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	74			
	1	2342536	GB		2000-04-12						
	2	1195975	EP		2002-04-10						
	3	99/66702	wo		1999-12-23						

	Application Number		
NEODIA TION DIOOL COURT	Filing Date		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Jeffre	ey Wilson
( Not for submission under 37 CFR 1.99)	Art Unit		
,	Examiner Name		
	Attorney Docket Numb	er	DYOUP0317US

If you wis	h to a	dd add	ditional Foreign Patent Document citation information please click the Add	button	Add	
			NON-PATENT LITERATURE DOCUMENTS		Remove	
Examiner   Cite   Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the ite (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						tem Ts
	1					
If you wisi	h to a	dd add	ditional non-patent literature document citation information please click the	Add bu	utton Add	
			EXAMINER SIGNATURE			
Examiner	Signa	ture	Date Conside	ered		
			f reference considered, whether or not citation is in conformance with MPE presence and not considered. Include copy of this form with next community			gh a

16e Knr. Oxee of USPTO Patent Documents at were USPTO\_GOV or MPEP 901.64. I Enter office that issued the document, by the Involetor code (WIPO Standard ST.3). "For Implantee patent for Comment, he crickless on the year of the Implant or precede the sent and replant document." I Knr. of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. "Applicant is to place a check mark here if English languages the resistance in a standard."

# Application Number Filing Date Filing Date Filing Date Filing Market Proceedings of the P

## CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98	to make the	appropriate	selection(s	s):
---------------	----------	----------	-------------	-------------	-------------	-----

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eVI).

# OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 179(c) and the statement. See 37 CFR 179(c) and the statement. See 37 CFR 179(c) and the statement is set to the statement of the statement of

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

## SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

form of the signature.							
Signature	/Don W. Bulson/	Date (YYYY-MM-DD)	2006-05-22				
Name/Print	Don W. Bulson	Registration Number	28192				

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, and Superinteed for Commence, P. 0. Bot 1450, Alexandria, V.32.11.450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.32.213.1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.